Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. / Schmid, Johannes Martin; Würtzen, Peter A; Siddhuraj, Premkumar; Jogdand, Prajakta; Petersen, Claus Gregers; Dahl, Ronald; Erjefält, Jonas S; Hoffmann, Hans Jürgen.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, No. 5, 05.2021, p. 1528-1538.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Schmid, JM, Würtzen, PA, Siddhuraj, P, Jogdand, P, Petersen, CG, Dahl, R, Erjefält, JS & Hoffmann, HJ 2021, 'Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients', Allergy: European Journal of Allergy and Clinical Immunology, vol. 76, no. 5, pp. 1528-1538. https://doi.org/10.1111/all.14264

APA

Schmid, J. M., Würtzen, P. A., Siddhuraj, P., Jogdand, P., Petersen, C. G., Dahl, R., Erjefält, J. S., & Hoffmann, H. J. (2021). Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. Allergy: European Journal of Allergy and Clinical Immunology, 76(5), 1528-1538. https://doi.org/10.1111/all.14264

CBE

Schmid JM, Würtzen PA, Siddhuraj P, Jogdand P, Petersen CG, Dahl R, Erjefält JS, Hoffmann HJ. 2021. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. Allergy: European Journal of Allergy and Clinical Immunology. 76(5):1528-1538. https://doi.org/10.1111/all.14264

MLA

Vancouver

Schmid JM, Würtzen PA, Siddhuraj P, Jogdand P, Petersen CG, Dahl R et al. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. Allergy: European Journal of Allergy and Clinical Immunology. 2021 May;76(5):1528-1538. https://doi.org/10.1111/all.14264

Author

Schmid, Johannes Martin ; Würtzen, Peter A ; Siddhuraj, Premkumar ; Jogdand, Prajakta ; Petersen, Claus Gregers ; Dahl, Ronald ; Erjefält, Jonas S ; Hoffmann, Hans Jürgen. / Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. In: Allergy: European Journal of Allergy and Clinical Immunology. 2021 ; Vol. 76, No. 5. pp. 1528-1538.

Bibtex

@article{38bd9739dec042da9b1c68875aaa2397,
title = "Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients",
abstract = "BACKGROUND: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long-term tolerance.OBJECTIVE: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue.METHODS: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n=18) or to an open control group (n=6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years treatment and every 6 months in the follow-up year. Nasal and cutaneous allergen challenge tests were performed annually. Leucocyte subsets were assessed in nasal mucosa biopsies at baseline and after treatment.RESULTS: Subcutaneous immunotherapy led to a 447-fold decrease in basophil sensitivity during the first treatment year. This remained hundredfold lower than baseline during the 3 year-treatment period and tenfold lower during the follow-up year (n=18, p=0.03). Decrease in basophil sensitivity after three weeks of treatment predicted long-term improvement in seasonal combined symptom and medication scores (ῥ=-0.69, p=0.0027) during three years of treatment. AUC of IgE blocking factor correlated to nasal allergen challenge (ῥ =0.63, p=0.0012) and SPT (ῥ =0.45, p=0.03). Plasma cell numbers in the nasal mucosa increased during treatment (p=0.02).CONCLUSION: Decrease in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinical outcome of this treatment.",
keywords = "IgE-blocking factor, allergen-specific IgE, basophil activation test, basophil sensitivity measurement, facilitated antigen binding",
author = "Schmid, {Johannes Martin} and W{\"u}rtzen, {Peter A} and Premkumar Siddhuraj and Prajakta Jogdand and Petersen, {Claus Gregers} and Ronald Dahl and Erjef{\"a}lt, {Jonas S} and Hoffmann, {Hans J{\"u}rgen}",
note = "This article is protected by copyright. All rights reserved.",
year = "2021",
month = may,
doi = "10.1111/all.14264",
language = "English",
volume = "76",
pages = "1528--1538",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Online",
number = "5",

}

RIS

TY - JOUR

T1 - Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients

AU - Schmid, Johannes Martin

AU - Würtzen, Peter A

AU - Siddhuraj, Premkumar

AU - Jogdand, Prajakta

AU - Petersen, Claus Gregers

AU - Dahl, Ronald

AU - Erjefält, Jonas S

AU - Hoffmann, Hans Jürgen

N1 - This article is protected by copyright. All rights reserved.

PY - 2021/5

Y1 - 2021/5

N2 - BACKGROUND: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long-term tolerance.OBJECTIVE: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue.METHODS: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n=18) or to an open control group (n=6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years treatment and every 6 months in the follow-up year. Nasal and cutaneous allergen challenge tests were performed annually. Leucocyte subsets were assessed in nasal mucosa biopsies at baseline and after treatment.RESULTS: Subcutaneous immunotherapy led to a 447-fold decrease in basophil sensitivity during the first treatment year. This remained hundredfold lower than baseline during the 3 year-treatment period and tenfold lower during the follow-up year (n=18, p=0.03). Decrease in basophil sensitivity after three weeks of treatment predicted long-term improvement in seasonal combined symptom and medication scores (ῥ=-0.69, p=0.0027) during three years of treatment. AUC of IgE blocking factor correlated to nasal allergen challenge (ῥ =0.63, p=0.0012) and SPT (ῥ =0.45, p=0.03). Plasma cell numbers in the nasal mucosa increased during treatment (p=0.02).CONCLUSION: Decrease in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinical outcome of this treatment.

AB - BACKGROUND: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long-term tolerance.OBJECTIVE: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue.METHODS: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n=18) or to an open control group (n=6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years treatment and every 6 months in the follow-up year. Nasal and cutaneous allergen challenge tests were performed annually. Leucocyte subsets were assessed in nasal mucosa biopsies at baseline and after treatment.RESULTS: Subcutaneous immunotherapy led to a 447-fold decrease in basophil sensitivity during the first treatment year. This remained hundredfold lower than baseline during the 3 year-treatment period and tenfold lower during the follow-up year (n=18, p=0.03). Decrease in basophil sensitivity after three weeks of treatment predicted long-term improvement in seasonal combined symptom and medication scores (ῥ=-0.69, p=0.0027) during three years of treatment. AUC of IgE blocking factor correlated to nasal allergen challenge (ῥ =0.63, p=0.0012) and SPT (ῥ =0.45, p=0.03). Plasma cell numbers in the nasal mucosa increased during treatment (p=0.02).CONCLUSION: Decrease in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinical outcome of this treatment.

KW - IgE-blocking factor

KW - allergen-specific IgE

KW - basophil activation test

KW - basophil sensitivity measurement

KW - facilitated antigen binding

UR - http://www.scopus.com/inward/record.url?scp=85082039301&partnerID=8YFLogxK

U2 - 10.1111/all.14264

DO - 10.1111/all.14264

M3 - Journal article

C2 - 32145088

VL - 76

SP - 1528

EP - 1538

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 5

ER -